MCOLN1 and neoplasm: Silencing or pharmacological inhibition of TRPML1 in aggressive triple-negative breast cancer reduced invasion and tumor growth in vitro and in vivo [44] and diminished the proliferation of cancer cells expressing oncogenic HRAS [45].